-
Sarepta Announces Plans to Submit sNDAs for AMONDYS 45 and VYONDYS 53
Today, Sarepta Therapeutics announced plans to submit supplemental New Drug Applications (sNDAs) to the U.S.
-
Sarepta Therapeutics is preparing to submit supplemental new drug applications (sNDAs) to the FDA for converting the accelerated approvals of AMONDYS 45 and VYONDYS 53 to traditional approvals
Sarepta Therapeutics is preparing to submit supplemental new drug applications (sNDAs) to the FDA for
-
The CureDuchenne Clinic Relocates in Greater Dallas to Meet Rising Demand for Specialized Neuromuscular Care
Expanded Facility Delivers Comprehensive, Multidisciplinary Care, Removing Barriers for Patients with Duchenne and Becker Muscular
-
MDA 2026: FDA decision on deramiocel for DMD expected by August
The latest Phase 3 trial results continue showing that deramiocel, an investigational cell therapy for
-
Living with Duchenne grants me unique insight into accessible design
For most of my life, Duchenne muscular dystrophy has defined how I navigate the world.
-
How to find a Duchenne specialist and certified care center
Riketa Smith, a certified medical assistant, shares resources families can use to identify Duchenne specialists
-
Advocating for your child at Duchenne doctor visits
Sheryl Marrazzo shares advice for fellow caregivers on preparing for medical appointments, advocating with facts,
-
MDA 2026: Dyne therapy boosts strength, cognition in DM1
Myotonic dystrophy type 1 (DM1) patients in a Phase 1/2 clinical trial saw gains in
-
Sarepta Announces Initiation of Screening and Enrollment for ENDEAVOR Cohort 8 in Non-Ambulatory Individuals Living with Duchenne
Sarepta Therapeutics, Inc. has announced screening and enrollment are underway in Cohort 8 of the
-
MDA 2026: Duvyzat shows DMD benefits even at lower dose levels
Treatment with Duvyzat (givinostat) was associated with functional gains in boys with Duchenne muscular dystrophy (DMD)
